Qiagen N.V. (ETR: QIA)
Market Cap | 9.93B |
Revenue (ttm) | 1.76B |
Net Income (ttm) | 83.32M |
Shares Out | n/a |
EPS (ttm) | 0.37 |
PE Ratio | 119.23 |
Forward PE | n/a |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 853,874 |
Average Volume | 478,874 |
Open | 44.75 |
Previous Close | 44.65 |
Day's Range | 44.44 - 44.96 |
52-Week Range | 36.59 - 45.02 |
Beta | 0.40 |
RSI | 66.59 |
Earnings Date | Feb 3, 2025 |
About Qiagen
Qiagen N.V. offers sample to insight solutions that transform biological materials into molecular insights. The company provides sample technology consumables, such as nucleic stabilization and purification kits for sample materials, manual and automated processing for genotyping, gene expression, and viral and bacterial analysis, as well as silica membranes and magnetic bead technologies; secondary sample technology consumables, such as kits and components for purification of nucleic acids from secondary sample materials; and instruments for n... [Read more]
Financial Performance
In 2023, Qiagen's revenue was $1.97 billion, a decrease of -8.23% compared to the previous year's $2.14 billion. Earnings were $341.30 million, a decrease of -19.35%.
Financial numbers in USD Financial StatementsNews
QIAGEN Announces Details for Completion of Synthetic Share Repurchase of up to Approximately $300 Million
VENLO, the Netherlands--(BUSINESS WIRE)--QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced details for completion of the synthetic share repurchase plan to return up to approxima...
Qiagen NV (QGEN) Announces Fourth Quarter 2024 Results Release and Conference Call
Qiagen NV (QGEN) Announces Fourth Quarter 2024 Results Release and Conference Call
QIAGEN N.V. to Release Results for Q4 2024 and Hold Webcast
QIAGEN N.V. (NYSE: QGEN) (Frankfurt Stock Exchange: QIA) announced plans to release results for the fourth quarter 2024. Press release date / time: Wednesday, February 5, shortly after 22:05 Frankfurt...
QIAGEN N.V. to Release Results for Q4 2024 and Hold Webcast
VENLO, the Netherlands--(BUSINESS WIRE)--QIAGEN N.V. (NYSE: QGEN) (Frankfurt Stock Exchange: QIA) announced plans to release results for the fourth quarter 2024. Press release date / time: Wednesday, ...
Qiage announces $300M buyback plan
Qiagen N.V. announces plan to return $300M to shareholders through synthetic share repurchase, part of $1B commitment by 2028.
Qiagen NV Announces $300 Million Synthetic Share Repurchase Plan
Qiagen NV Announces $300 Million Synthetic Share Repurchase Plan
QIAGEN to Return Approximately $300 Million to Shareholders Through a Synthetic Share Repurchase
QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced a new plan to return up to approximately $300 million (maximum EUR 281 million) to shareholders through a synthetic share repurc...
QIAGEN to Return Approximately $300 Million to Shareholders Through a Synthetic Share Repurchase
VENLO, Netherlands--(BUSINESS WIRE)---- $QGEN #QIAGEN--QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced a new plan to return up to approximately $300 million (maximum EUR 281 mi...
EQS-Adhoc: QIAGEN N.V.: QIAGEN to return approximately $300 million to shareholders through a synthetic share repurchase
EQS-Ad-hoc: QIAGEN N.V. / Key word(s): Share Buyback QIAGEN N.V.: QIAGEN to return approximately $300 million to shareholders through a synthetic share repurchase 12-Jan-2025 / 18:55 CET/CEST Disclosu...
Qiagen NV (QGEN) Enhances QIAcuity Digital PCR System with Advanced Multiplexing Capabilities
Qiagen NV (QGEN) Enhances QIAcuity Digital PCR System with Advanced Multiplexing Capabilities
QIAGEN Increases QIAcuity Digital PCR High-Order Multiplexing Capabilities to Gain Deeper Insights From Biological Samples
QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced a significant increase in the powerful capabilities of its QIAcuity Digital PCR (dPCR) system with a more than two-fold increase in t...
QIAGEN Increases QIAcuity Digital PCR High-Order Multiplexing Capabilities to Gain Deeper Insights From Biological Samples
VENLO, Netherlands--(BUSINESS WIRE)--QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced a significant increase in the powerful capabilities of its QIAcuity Digital PCR (dPCR) system wi...
QIAGEN secures U.S. clearance for first QIAstat-Dx mini gastrointestinal panel to support year-round outpatient care
QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the U.S. regulatory clearance of the first in a series of QIAstat-Dx Gastrointestinal Panel tests for clinical use. This clearance by...
QIAGEN secures U.S. clearance for first QIAstat-Dx mini gastrointestinal panel to support year-round outpatient care
GERMANTOWN, Md., & VENLO, The Netherlands--(BUSINESS WIRE)--QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the U.S. regulatory clearance of the first in a series of QIAstat-Dx Gast...
QIAGEN Supports UK Initiative to Sequence Genomes of 100,000 Newborns With Expert-Curated Genomic Content
REDWOOD CITY, Calif. & VENLO, The Netherlands--(BUSINESS WIRE)--QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced that it has partnered with Genomics England to support the delivery o...
EY wins first Dax audit client since Wirecard scandal
Big Four firm handed mandate by biotech group Qiagen despite ban on taking on listed German companies
QIAGEN Launches AI-Extension of Ingenuity Pathway Analysis for Automatic Interpretation of Biological Data
REDWOOD CITY, Calif. & VENLO, the Netherlands--(BUSINESS WIRE)--QIAGEN (NYSE: QGEN, Frankfurt Prime Standard: QIA) today announced the launch of Ingenuity Pathway Analysis (IPA) Interpret, a new featu...
QIAGEN Reaches Milestone With Over 1,000 Placements of EZ2 Connect Sample Preparation Instrument, Driving Laboratory Automation
VENLO, Netherlands--(BUSINESS WIRE)---- $QGEN #QIAGEN--QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced it has reached a significant milestone with over 1,000 placements of the EZ2 C...
QIAGEN Strengthens QIAstat-Dx With New Barcelona Site to Drive Growth in Infectious Diseases and Precision Medicine Testing
QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced plans to move its QIAstat-Dx operations within the Barcelona area to a new site in Esplugues de Llobregat as part of a multi-year inv...
QIAGEN Strengthens QIAstat-Dx With New Barcelona Site to Drive Growth in Infectious Diseases and Precision Medicine Testing
BARCELONA, Spain & VENLO, the Netherlands--(BUSINESS WIRE)--QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced plans to move its QIAstat-Dx operations within the Barcelona area to a ne...
QIAGEN launches novel tools for customizing digital PCR assays and NGS panels for microbial analysis
QIAGEN introduces market's first customizable digital PCR assay design tool with advanced design algorithms tailored for diverse microbial applications and custom NGS panels // First-of-its-kind Custo...
Wellington Management Group LLP's Strategic Acquisition of Qiagen NV Shares
Wellington Management Group LLP's Strategic Acquisition of Qiagen NV Shares
Qiagen N.V. (QGEN) Q3 2024 Earnings Call Transcript
Qiagen N.V. (NYSE:QGEN) Q3 2024 Earnings Conference Call November 7, 2024 9:30 AM ETCompany ParticipantsJohn Gilardi - VP, Head of Corporate Communications...
Diagnostics firm Qiagen reports rise in third-quarter revenue
Qiagen reported a rise in third-quarter revenue on Wednesday, owing to strong sales of its diagnostic devices.
QIAGEN receives FDA clearance of QIAstat-Dx meningitis/encephalitis panel to support emergency diagnostics
QIAstat-Dx Meningitis/Encephalitis Panel cleared in the U.S. for use in clinical settings to help diagnose central nervous system infections // Fourth FDA clearance marks milestone in 2024 in successf...